MRK Merck
- Official Name: MERCK & CO., INC.
- Headquarters: 126 East Lincoln Avenue, P.O. Box 2000, RAHWAY, NJ, 07065 US
- CEO: Robert M. Davis
- Website: merck.com
- Key Investor: VANGUARD GROUP INC | 10%
- Dedicated Investor: KAHN BROTHERS GROUP INC | 8.94%
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-14 | 1 | Won by 6.122 | 2.558 - (3.564) | ||
| 2025-07-21 | 2 | Lost by 1.966 | (4.757) - (2.791) | ||
| 2025-07-28 | 3 | Lost by 11.372 | 6.038 - 17.410 | ||
| 2025-07-29 | 2R | Lost by 2.763 | (2.502) - 0.261 | ||
| 2025-08-04 | 4 | Lost by 2.386 | (4.408) - (2.022) | ||
| 2025-08-07 | 1R | Won by 1.796 | 1.470 - (0.326) | ||
| 2025-08-11 | 5 | Won by 9.753 | 4.058 - (5.695) | ||
| 2025-08-18 | 6 | Won by 2.746 | 5.686 - 2.940 | ||
| 2025-08-20 | 1R | Won by 0.713 | (0.006) - (0.719) | ||
| 2025-08-21 | 2R | Won by 1.773 | 1.535 - (0.238) | ||
| 2025-08-25 | 7 | Lost by 0.971 | 1.334 - 2.305 | ||
| 2025-09-01 | 8 | Lost by 2.893 | (1.385) - 1.508 | ||
| 2025-09-03 | 2R | Lost by 0.371 | (1.509) - (1.138) | ||
| 2025-09-04 | 3R | Lost by 1.962 | (0.180) - 1.782 | ||
| 2025-09-08 | 9 | Won by 0.521 | (0.025) - (0.546) | ||
| 2025-09-15 | 10 | Lost by 10.525 | (3.671) - 6.854 | ||
| 2025-09-22 | 11 | Won by 2.507 | (0.730) - (3.237) | ||
| 2025-09-29 | 12 | Lost by 5.315 | (2.209) - 3.106 | ||
| 2025-10-06 | 13 | Won by 12.402 | 11.393 - (1.009) | ||
| 2025-10-13 | 14 | Won by 4.192 | (3.638) - (7.830) | ||
| 2025-10-20 | 15 | Lost by 0.630 | 0.764 - 1.394 |
Latest News
Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know
Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put the pace of future increase...
AbbVie vs. Merck: Which Pharma Stock Offers Better Value?
AbbVie Inc. (NYSE:ABBV) and Merck & Co., Inc. (NYSE:MRK) have something important in common that is important for investors, which is that both mu...
Merck Stock: Watch This Price, Prepare To Profit From This Trade
Merck stock has been in an uptrend. A bullish options strategy aims to profit if the drugmaker's stock keeps rising.
Merck’s Rally Reflects Renewed Confidence, but Has the Market Priced in Too Much?
Merck & Co., Inc. (NYSE:MRK) has surged over 38% in 2026 so far, outperforming the broader market. Merck is no longer being valued like a pharmace...
Moderna stock sinks as Wall Street turns cautious following blistering rally
Moderna sank as Wall Street grew more cautious on the company's valuation after a massive rally this year.
Moderna Tumbles 10% as Profit Taking Hits Cancer Vaccine Rally; BioNTech Eases, Pfizer Stays Put
Moderna stock is shedding 10% after a blistering cancer vaccine run, and the question now is whether profit takers know something the bulls don't...
What Is The Case For Waiting On Moderna Stock?
Moderna (MRNA) stock has gained 282.6% over the past three months, outpacing a 4.1% return for the S&P 500. The shares reached their highest close...
The Stocks That Will Get Investors Home Safe When Tech Cracks
When tech stocks crack, most investors discover too late that their portfolios were far more concentrated than they realized. Jim Cramer and others ar...
9 Of 11 Sectors Rise In Friday Trading As Cyclicals Lead
Nine of 11 sectors are higher in Friday’s regular session, with cyclical sectors holding the top three positions. The leaders are separated rather t...
AI Stocks Are Hurting. Look at These Other Sectors for Protection.
Investors are fleeing tech stocks due to artificial-intelligence worries. But many other sectors of the market look like a good bet.
How Has Merck's Story Changed?
Investors are pricing Merck (MRK) stock at 5.5 times sales, compared with 3.1 for the S&P 500. Shareholders paying that premium need to understand...
As chip stocks fall, investors are turning elsewhere in the market: Chart of the Day
Yahoo Finance Markets and Data Editor Jared Blikre takes a closer look at the latest market and sector action, highlighting what the sell-off in CoreW...
What Could Merck (MRK) Reveal At ESMO 2026 About Its Oncology Pipeline?
Merck (NYSE:MRK) plans to unveil first-time pivotal Phase 3 oncology data at ESMO 2026, including melanoma and endometrial cancer trials. The company ...
Discover which dow jones stocks are making waves on Thursday.
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
Why Healthcare Stocks Are Hot When the AI Trade Runs Cold
Healthcare—particularly equipment and services and pharmaceuticals—offers investors diversification from AI, according to one report.
Moderna Rallies 6% as Money Rotates Into Healthcare; BioNTech and Pfizer Edge Higher
Money is leaving the AI trade and landing in healthcare, but one mRNA name is surging at a pace that leaves its closest peers far behind, and a clinic...
AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow
Amgen and Merck both yield around 2.3% and have surged this year, but one of them is paying its dividend out of thin air while the other has a cash cu...
Merck & Co., Inc. (MRK) Reports Promising Skin Cancer Trial Results for Keytruda and Personalized mRNA Vaccine
Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “International Concentrated...
Nike, Moderna, Walmart Get a Lift as Traders Flee AI Stocks
Concerns about tech companies overspending on AI prompted investors to rotate out of the trade and seek value elsewhere.
IBT manager on therapeutics conference, oncology breakthroughs and five years of outperformance
International Biotechnology Trust Plc (LSE:IBT, OTC:IBITF) portfolio manager Marek Poszepczynski spoke with Proactive's Stephen Gunnion about eme...
Stock Market Today: Dow Rises, Nasdaq Tumbles As AI Worries Hit Major Players (Live Coverage)
The Dow Jones index rises Thursday ahead of more inflation data. Nvidia, Micron and AMD sell off on AI fears.
Where Could Johnson & Johnson's Next Growth Come From?
Johnson & Johnson (JNJ) stock trades at 29.1 times its earnings over the past twelve months, compared with 22.7 for the S&P 500. Investors pay...
Moderna Stock Is Soaring on Cancer Vaccine Buzz. Is It Too Late to Get In?
Moderna has surged more than 650% this year on cancer vaccine excitement, but analyst targets sit far below the current share price. Before you chase ...
Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stoc...
Defensives Lead Sectors In Thursday Trading As Technology Trails
Seven sectors are higher and four are lower in Thursday’s regular session, with defensive sectors holding two of the top three positions. The leader...
AI Fears Grip Markets as Tech Rotation Accelerates
As we enter the spooky season markets got an early fright as the tech stocks rotation accelerated alongside the fallout from a hot inflation reading.
AI Fears Grip Markets as Scary Tech Rotation Accelerates
As we enter the spooky season markets got an early fright as the tech stocks rotation accelerated alongside the fallout from a hot inflation reading.
Merck & Co. (NYSE:MRK): A Quality Investing Case With Strong ROIC but Revenue Growth Concerns
Merck & Co. (MRK) quality investing analysis: strong ROIC, cash conversion, low debt/FCF, but revenue growth misses Caviar Cruise screen.
Stock Market Today: Hot Inflation and a Neocloud Shakeout Sink the Nasdaq
Hotter September inflation revived Fed hike bets and a Gartner warning crushed AI neoclouds. Pharma caught a bid, BlackRock hit a record, BofA got fin...
Why Eli Lilly Became Wall Street’s Safe Haven on a Hot CPI Day
Eli Lilly (LLY:NYSE) stock rose roughly 4% on Wednesday, October 14, joining a broad rally in healthcare stocks. No major Lilly news drove it.
How Much Downside Is Left In Liquidia Stock?
Over the past month, shares of Liquidia (LQDA) have lost 59%, even as the S&P 500 gained 2.5%. Reuters reported that the stock dropped nearly 50% ...
What Could Send Regeneron Stock Higher?
Regeneron Pharmaceuticals (REGN) may get its next boost from an old deal rather than a new drug. Through the first half of 2026, Regeneron was paying ...
Discover which dow jones stocks are making waves on Wednesday.
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Wed...
Top S&P500 movers in Wednesday's session
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...
Lilly, Merck, AbbVie Stocks Surge. Why Healthcare Is Rallying Today.
Shares of Lilly, the world’s largest pharmaceutical company by market value, rallied above their 50-day moving average to mark their best level sinc...
Phanes Therapeutics announces first patient with colorectal cancer (CRC) dosed in clinical study of spevatamig
Phanes Therapeutics, Inc. (Phanes), a clinical-stage biotech company focused on innovative drug discovery and development in immuno-oncology (IO), ann...
These dow jones stocks are moving in today's session
Curious about the top performers within the dow jones index in the middle of the day on Wednesday? Dive into the list of today's session's t...
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wed...
Verastem Gets a New CEO, $250M, and a Shot at Another Cancer Drug
Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
MRK's Keytruda sales growth, earlier-stage launches and expanded indications could boost Q3 results, but biosimilar competition looms in 2028-202...
Merck CEO tells CNBC he expects breakthrough cancer vaccine will become faster to make
His comments come after Merck officially opened its new 120,000-square-foot research facility in the Greater Philadelphia area.
How to Turn $500,000 Into a Lazy $16,500 Yearly Passive Income Stream
Retirees watching CD rates scrape bottom and Treasury coupons lock in for a decade have a third option hiding in plain sight inside the Dow Jones Indu...
The Open Question Under Johnson & Johnson Stock's Price
Johnson & Johnson (JNJ) has introduced several new drugs recently, and current buyers of its stock may be betting on their commercial success. The...
Merck CEO Davis on new manufacturing site: Will meaningfully accelerate getting drugs to patients
CNBC’s Annika Kim Constantino sits down with Merck Chairman and CEO Rob Davis to discuss the company’s new manufacturing site in Pennsylvania, wha...
Nasdaq 100 Drops 1% on Hot CPI, SOXX Falls 7th Day: Stock Market Today
The Nasdaq 100 fell 1% by midday Wednesday after September CPI topped forecasts, pushing Treasury yields and rate-hike bets higher.
Single-Use Assemblies Global Market Report 2026-2030 | Capitalize on 22.8% CAGR as Thermo Fisher, Danaher, Sartorius, Merck, and Avantor Scale Modular Bioprocessing
Boost ROI with modular, customized systems that scale flexibly, cut cleaning and contamination costs, speed fill-finish, and localize sourcing to redu...
Dow Jones Industrial Average Monitor Update - A Look At 30 U.S. Large-Caps
Visible Alpha consensus expects the Dow Jones Industrial Average to deliver an 18.7% weighted price return in the medium term. Read more here.
J&J Selloff Exposes Medtech Strain: Is Pharma Carrying Healthcare Stocks?
The J&J selloff shows how medtech weakness can outweigh pharma strength, and what it means for healthcare stocks.
Is Amgen Stock Worth More Than Its Competitors?
Amgen (AMGN) competes in a tight peer group of six large drugmakers alongside AbbVie, Johnson & Johnson, Merck, Pfizer, and Bristol-Myers Squibb. ...
BNTX Stock Selloff Deepens Doubts: BMO Ties BNT113 Miss To Wider mRNA Cancer Vaccine Struggles
BMO Capital Markets analyst Evan David Seigerman said that the PFS miss for BNT113 “adds to a growing list of recent mRNA cancer vaccine setbacks”...
Merck (MRK) Dips More Than Broader Market: What You Should Know
Merck (MRK) concluded the recent trading session at $141.98, signifying a -2.39% move from its prior day's close.
What Does Bristol-Myers Squibb Offer That Pfizer Does Not?
Pfizer (PFE) and Bristol-Myers Squibb (BMY) are bought for the same underlying reason: the search for new drugs to replace older ones losing market ex...
What Is Eli Lilly Stock's Biggest Opportunity?
Investors are currently valuing Eli Lilly (LLY) stock at a premium, with shares priced at 39.5 times earnings compared with 21.9 for the S&P 500. ...
Explore the top gainers and losers within the dow jones index in today's session.
Uncover the latest developments among dow jones stocks in today's session. Stay tuned to the dow jones index's top gainers and losers on Tue...
Here’s What’s Dragging Down the Dow
A decent day for the Dow has completely flipped on its head.
Merck (MRK) Reports a Negative Operating Margin and Pays Out 266% of Earnings. What Explains Both?
Merck & Co., Inc. (NYSE:MRK) closed at $145.45 on October 12. The stock has returned 21% during the last six months, compared to a 21.25% return f...
Discover which dow jones stocks are making waves on Tuesday.
Curious about the dow jones stocks that are in motion on Tuesday? Join us as we explore the top movers within the dow jones index during today's ...
Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit
Johnson & Johnson stock is tumbling even after the healthcare giant raised its forecast again for full-year earnings and revenue.
BioNTech’s Cancer Drug Misses A Key Trial Goal – Citi Says Survival Data Could Preserve ‘A Meaningful Development Path’
BioNTech’s experimental cancer treatment combined with Merck’s Keytruda failed to significantly delay disease progression compared with Keytruda a...
MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
Moderna gains $4.2 billion in a week on cancer-vaccine optimism and Nasdaq-100 inclusion. Can its growth prospects justify its premium valuation?
Here's What to Expect From Merck & Co.'s Next Earnings Report
Merck & Co. is set to release its third-quarter earnings in a couple of weeks, and analysts are expecting its EPS to grow by a single digit.
Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA h...
Why Is BioNTech Stock Falling Tuesday?
BioNTech stock drops over 5% as BNT113 mRNA cancer trial misses PFS endpoint. Focus shifts to overall survival in HPV16+ HNSCC study.
Why A Biotech M&A Wave May Hit This Winter
Biotech stocks have slumped from their August highs. But experts say renewed M&A, likely coming, could catalyze them.
Can a Spinoff Fix Johnson & Johnson’s Medtech Problem?
Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter.
Johnson & Johnson Hikes Earnings Guidance but Pharma Growth Masks a MedTech Stumble. Stock Falls.
Johnson & Johnson says it is working to improve results in its medical-device business, where surgery revenue fell for the latest quarter.
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
RAHWAY, N.J., October 13, 2026--Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors
Cyclicals Lead Sectors In Tuesday Trading As Health Care Trails
Four sectors are higher and seven are lower in Tuesday’s regular session, with cyclical sectors holding two of the top three positions. Materials si...
Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of +2.37% and -0.15%, respectively, for the quarter ended September 2026. Do the ...
Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
RAHWAY, N.J., October 13, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that first-time results from ...
Global Cell Culture Market Report 2026: Size, Share, Trends and Forecast to 2030 | Capitalize on Biologics and Personalized Medicine with Thermo Fisher, Merck, Lonza and Sartorius
Dublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- "Cell Culture Market Report 2026" has been added to ResearchAndMarkets.com's offering. The gl...
Global Protein Labeling Market Report 2026: Size, Share, Trends, and 2030 Forecast | Capture a $4.89 Billion Market as Thermo Fisher, Merck, Bio-Rad, and Abcam Scale Automation
Dublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- "Protein Labeling Market Report 2026" has been added to ResearchAndMarkets.com's offering. Th...
Global Industrial Bioprocessing Market Report 2026: Size, Share, Trends and Forecast to 2030 | Capitalize on 9% CAGR with Thermo Fisher, Danaher, Merck and Sartorius
Boost ROI via partnerships, process intensification, single-use systems, modular bioreactors, efficient purification and capacity expansionDublin, Oct...
Global Bioprocessing Supplies Market Report 2026: Size, Share, Trends, and Forecast to 2030 | Capitalize on Single-Use Scale with Thermo Fisher, Danaher, Merck, Sartorius
Dublin, Oct. 13, 2026 (GLOBE NEWSWIRE) -- "Bioprocessing Supplies Market Global Report 2026" has been added to ResearchAndMarkets.com's...
Global Bioconjugation Reagents Market Report 2026: Size, Trends, and Forecast to 2030 | Accelerate ADC and Click Chemistry Growth with Thermo Fisher, Merck, Danaher, and Bio-Rad
Bioconjugation Reagents Market to Reach $3.87 Billion by 2030 as Precision Medicine and Antibody-Drug Conjugate Demand ExpandsDublin, Oct. 13, 2026 (G...
Merck To Present First-Time Results From Three Pivotal Clinical Trials At ESMO Congress; Data Demonstrate Improvements In Recurrence-Free Survival And Distant Metastasis-Free Survival Versus KEYTRUDA Alone In Patients With Completely Resected Stage IIB-IV Melanoma
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that first-time results from three pivotal clinical trials wil...
S&P Hits All-Time Highs, AI Trade Does All The Work
From June we saw money rotate out of tech into reflationary sectors, also software, explains Amrita Roy and Uttam Dey. Now, money is moving back into ...
Moderna Stock Soared 14% as NIH Plans COVID-Style Push for Cancer Vaccines
Key TakeawaysModerna stock surged 14. 2% on October 9 after reports of an NIH-backed initiative to accelerate cancer vaccine development.
Where Could Moderna's Next Growth Come From?
Moderna (MRNA) stock has returned 621% over the past twelve months, easily outpacing the S&P 500's 17.0% return. Yet the company's sales...
Uncover the latest developments among dow jones stocks in today's session.
Curious about the top performers within the dow jones index one hour before the close of the markets on Monday? Dive into the list of today's ses...
Could Merck (MRK) Have A New DME Option After Its Late Stage Trial Data?
Merck (NYSE:MRK) reported one year pivotal Phase 2b/3 data for remigromig in diabetic macular edema, showing non inferior efficacy to a leading anti V...
Moderna stock surges more than 600% in 2026
The vaccine maker's stock gained 18% last week after a report on a planned NIH cancer vaccine initiative and its addition to the Nasdaq-100
Merck (MRK) Could Be 7% Below Fair Value On Phase III Cancer Vaccine Results
Merck (MRK) is back in focus after reporting positive Phase III results from its personalized mRNA cancer vaccine program with Moderna, a development ...
Citigroup Maintains Neutral on Merck & Co, Raises Price Target to $145
Citigroup analyst Geoff Meacham maintains Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $125 to $145.
Jefferies cuts Merck’s remigromig sales forecast after eye-disease trial raises concerns
Jefferies has cut its peak sales forecast for Merck & Co Inc (NYSE:MRK, XETRA:6MK)’s experimental eye treatment remigromig by 60% after detailed...
BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?
Bristol Myers shares surge 35.8% as its Growth Portfolio and pipeline progress fuel momentum, but generic competition and valuation warrant caution.
Tempus AI Expands Strategic Collaborations to Drive Future Growth
TEM is expanding its precision medicine footprint through strategic collaborations with Moderna, Merck and Recursion, paving the way for future revenu...
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research fundi...
Wall Street Bulls Look Optimistic About Merck (MRK): Should You Buy?
Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic...
Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on D...
Prediction: AbbVie’s Next Billion-Dollar Opportunity Is Taking Shape
Skyrizi and Rinvoq are growing fast, a blockbuster acquisition just closed, and the FDA handed AbbVie a fresh approval, yet the stock sits just shy of...
RBC Capital Maintains Sector Perform on Merck & Co, Lowers Price Target to $145
RBC Capital analyst Trung Huynh maintains Merck & Co (NYSE:MRK) with a Sector Perform and lowers the price target from $150 to $145.
Palantir CTO Says Some AI Researchers Are So Sure It Will Cure Cancer They’ve Started 'Smoking' — Warns Both AI Extremes Reflect ‘Social Delusion’
Palantir CTO Shyam Sankar calls AI doomsday predictions theological, while warning that extreme optimism amounts to ‘mass psychosis,'
3 Profitable Stocks We Approach with Caution
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green tod...
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.
Reported Saturday, Merck’s Remigromig Delivers Mean BCVA Gains Of 9.1 Letters At 0.5 Mg And 8.7 Letters At 0.8 Mg Versus 11.8 For Ranibizumab, Meeting Non-Inferiority, With No Secondary Endpoint Showing Superiority
Remigromig demonstrated non-inferiority in mean change from baseline in best corrected visual acuity versus ranibizumab at one year in patients with d...
SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH
The ASH meeting runs Dec. 12-Dec. 15 in New Orleans. Sellas is listed at Booth 138, and more than 275 exhibitors are expected.